Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

Phase 4CompletedNCT00080327

Otsuka Pharmaceutical Development & Commercialization, Inc.370 enrolled

Overview

A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

370

Tablets, Oral, 2mg, Once daily, 6 weeks.

Tablets, Oral, 5mg, Once daily, 6 weeks.

Tablets, Oral, 10mg, Once daily, 6 weeks.

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months

Bristol-Meyers Squibb Call Center

Wallingford, Connecticut, United States

Change at endpoint in schizophrenia rating scale

Clinical Global Improvement scale at endpoint and time to response

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.